Last reviewed · How we verify
Albumin administration
Albumin administration is a Colloid volume expander Small molecule drug developed by Rennes University Hospital. It is currently FDA-approved for Hypovolemia and shock due to burns, hemorrhage, or trauma, Hypoproteinemia and edema in liver disease or nephrotic syndrome, Plasma volume expansion during major surgery or critical illness.
Albumin administration increases plasma oncotic pressure and restores intravascular volume by providing a colloid solution that expands the blood compartment.
Albumin administration increases plasma oncotic pressure and restores intravascular volume by providing a colloid solution that expands the blood compartment. Used for Hypovolemia and shock due to burns, hemorrhage, or trauma, Hypoproteinemia and edema in liver disease or nephrotic syndrome, Plasma volume expansion during major surgery or critical illness.
At a glance
| Generic name | Albumin administration |
|---|---|
| Sponsor | Rennes University Hospital |
| Drug class | Colloid volume expander |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Hematology |
| Phase | FDA-approved |
Mechanism of action
Human serum albumin is a naturally occurring protein that acts as a volume expander and maintains colloid osmotic pressure in the bloodstream. It is used to restore circulating blood volume in conditions of hypovolemia, such as severe burns, hemorrhage, or hypoproteinemia. Albumin also serves as a carrier protein for various endogenous and exogenous substances.
Approved indications
- Hypovolemia and shock due to burns, hemorrhage, or trauma
- Hypoproteinemia and edema in liver disease or nephrotic syndrome
- Plasma volume expansion during major surgery or critical illness
Common side effects
- Hypervolemia / fluid overload
- Hypersensitivity reactions
- Hypertension
- Chills and fever
- Nausea
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (PHASE3)
- CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer (PHASE1)
- Hyaluronic Acid and Albumin-PRF in Non-Surgical Periodontal Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albumin administration CI brief — competitive landscape report
- Albumin administration updates RSS · CI watch RSS
- Rennes University Hospital portfolio CI
Frequently asked questions about Albumin administration
What is Albumin administration?
How does Albumin administration work?
What is Albumin administration used for?
Who makes Albumin administration?
What drug class is Albumin administration in?
What development phase is Albumin administration in?
What are the side effects of Albumin administration?
Related
- Drug class: All Colloid volume expander drugs
- Manufacturer: Rennes University Hospital — full pipeline
- Therapeutic area: All drugs in Critical Care / Hematology
- Indication: Drugs for Hypovolemia and shock due to burns, hemorrhage, or trauma
- Indication: Drugs for Hypoproteinemia and edema in liver disease or nephrotic syndrome
- Indication: Drugs for Plasma volume expansion during major surgery or critical illness
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing